Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Day One Biopharmaceutical Q1 EPS $(0.35) Beats $(0.44) Estimate, Sales $30.76M Beat $30.24M Estimate

Author: Benzinga Newsdesk | May 06, 2025 03:04pm
Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.44) by 20.45 percent. This is a 51.39 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $30.76 million which beat the analyst consensus estimate of $30.24 million by 1.73 percent.

Posted In: DAWN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist